In this article, we will discuss the 7 Best ASX Stocks to Buy Now
While the Australian market is relatively well-positioned, it is vulnerable to broader market shocks, says SG Hiscock & Company (an Australian boutique investment manager). During the meeting on May 20, the RBA Board decided to reduce the cash rate target by 0.25% to 3.85%. For the broader market, the critical feature of this meeting, as well as the media briefing, was confirmation that the Board assessed the possibility of an even larger rate cut of 0.5%. Considering the still-elevated levels of global uncertainty, the RBA is expected to take a cautiously dovish stance toward further rate cuts, as per Grant Feng (Vanguard Senior Economist).
What Lies Ahead for the Australian Economy?
There has been some easing of the US-China trade tensions, reducing the external uncertainty and growth concerns, added Feng. Overall, Feng expects the Australian economy to grow ~2% over 2025, with the easing of policy partly mitigating the impact of uncertainty. The inflation is expected to stay in the 2%–3% band targeted by the RBA, though it is expected to be in the upper half of this range. Furthermore, the supply-side weakness, mainly the lackluster productivity growth, is expected to hold back progress on disinflation, added Feng.
Amidst these trends, let us now have a look at the 7 Best ASX Stocks to Buy Now
An experienced fund advisor setting parameters on investments with remaining maturities of one to three years.
Our Methodology
To list the 7 Best ASX Stocks to Buy Now, we used a screener to shortlist the ASX stocks listed on the US exchanges. After getting the list, we chose the ones popular among hedge funds, as of Q1 2025. Finally, the stocks have been ranked in ascending order of their hedge fund sentiments.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
7 Best ASX Stocks to Buy Now
7. Telix Pharmaceuticals Limited (NASDAQ:TLX)
Number of Hedge Fund Holders: N/A
Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the 7 Best ASX Stocks to Buy Now. On June 23, the company announced that the US FDA approved a label expansion for Illuccix® (kit for the preparation of gallium Ga-68 gozetotide, for injection) to include patient selection for radioligand therapy (RLT) in the pre-taxane setting.
This update gets applied to Illuccix’s third indication, for selecting patients who are indicated for PSMA-directed therapy as described in the Prescribing Information of the therapeutic products. The label expansion follows the approval by the US FDA of an expanded label for Pluvicto® (lutetium Lu177 vipivotide tetraxetan) for use in metastatic castration-resistant prostate cancer (mCRPC) patients after the treatment with androgen receptor pathway inhibitor (ARPI) therapy and before chemotherapy. Now that RLT is approved for earlier usage in the patient journey, the clinical utilization of Illuccix® is projected to increase by a minimum of 20,000 scans annually.
In Q1 2025, Telix Pharmaceuticals Limited (NASDAQ:TLX)’s unaudited revenue came in at ~$186 million, representing an increase of 62% over the prior year corresponding quarter (Q1 2024: $115 million) and a QoQ rise of 31% (Q4 2024: $142 million). This includes $151 million from global sales of Illuccix® and $33 million from RLS Radiopharmacies (RLS) since the acquisition was completed on 27 January 2025.
Telix Pharmaceuticals Limited (NASDAQ:TLX) stated that Illuccix continued to gain market share and maintain price stability amidst competition. Furthermore, Telix Pharmaceuticals Limited (NASDAQ:TLX) happens to be the only company with 2 FDA-approved PSMA-PET imaging agents – Illuccix and Gozellix. This allows it to broaden patient reach and maximize choice for the customers. Telix Pharmaceuticals Limited (NASDAQ:TLX)’s stock has a consensus one-year price target of $22.90.
